1. Home
  2. GALT vs OBIO Comparison

GALT vs OBIO Comparison

Compare GALT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

N/A

Current Price

$2.90

Market Cap

397.3M

Sector

Health Care

ML Signal

N/A

OBIO

Orchestra BioMed Holdings Inc.

N/A

Current Price

$7.30

Market Cap

473.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GALT
OBIO
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.3M
473.0M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
GALT
OBIO
Price
$2.90
$7.30
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $13.14
AVG Volume (30 Days)
185.4K
★ 496.2K
Earning Date
11-16-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.84
33.13
EPS
★ N/A
N/A
Revenue
N/A
★ $33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$52.64
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 1169.22
52 Week Low
$2.03
$3.46
52 Week High
$7.13
$7.45

Technical Indicators

Market Signals
Indicator
GALT
OBIO
Relative Strength Index (RSI) 35.26 68.96
Support Level $2.78 $3.81
Resistance Level $3.30 N/A
Average True Range (ATR) 0.30 0.52
MACD -0.03 0.17
Stochastic Oscillator 5.13 94.89

Price Performance

Historical Comparison
GALT
OBIO

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: